<DOC>
	<DOCNO>NCT02108002</DOCNO>
	<brief_summary>Background : - Von Hippel-Lindau ( VHL ) disease rare gene disease . People VHL often brain tumor call hemangioblastoma . Standard treatment tumor risky surgery . Researchers want find new way treat people tumor . They want see drug fight cancer might slow growth hemangioblastomas people VHL . Some people VHL mutation make abnormal protein . Tumors form people abnormal protein broken quickly . The cancer drug may work tumor prevent breakdown protein . Objective : - To study drug vorinostat affect hemangioblastomas people VHL . Eligibility : - Adults least 18 old hemangioblastomas VHL . Design : - Participants must already study 03-N-0164 . They must tumor surgery schedule . - Participants must stop take medication 14 day surgery . - One week surgery , participant enter hospital . They screen medical history physical neurological exam . They give blood urine sample . Participants electrocardiogram . For test , small sticky patch put arm , leg , chest . Participants lie still minute machine record heart rate rhythm . - Participants take one vorinostat mouth day 7 day . - Participants blood drawn week check side effect . - Participants tumor remove surgery . Researchers study tumor tissue effect study drug . - A nurse call participant 1 month surgery check side effect .</brief_summary>
	<brief_title>Effect Vorinostat Nervous System Hemangioblastomas Von Hippel-Lindau Disease ( Missense Mutation Only )</brief_title>
	<detailed_description>Background Central Nervous System ( CNS ) hemangioblastomas common tumor find familial neoplasia syndrome , Von Hippel-Lindau ( VHL ) . Hemangioblastomas cause significant morbidity mortality . While surgical resection treatment choice CNS hemangioblastomas , associate morbidity death . There critical need new non-invasive treatment VHL-associated CNS hemangioblastomas . Vorinostat histone deacetylase inhibitor ( HDACi ) FDA-approved treatment refractory cutaneous T-cell lymphoma ( CTCL ) . Vorinostat test hematologic malignancy solid tumor . Recent data suggest vorinostat may potent therapeutic effect treatment VHL-associated hemangioblastomas patient missense germline mutation VHL gene . In VHL mutation type , abnormal VHL protein content active , lead tumor formation growth . In missense mutation VHL disease , tumor cell contain malformed VHL protein partially active . However , protein degrade quickly normal cellular mechanism . Vorinostat prevent degradation malformed protein within tumor . Increased protein lead slow growth tumor . Objective To determine whether vorinostat reduces degradation mutant VHL protein VHL patient germline missense mutation . Eligibility Adult patient ( age great equal 18 year ) know germline missense VHL gene mutation require surgical resection hemangioblastoma . Design We intend conduct pilot study vorinostat six patient hemangioblastomas cause significant symptom tumor growth . Vorinostat administer patient deemed surgical candidate . Patients receive one ( 1 ) dose 400 mg vorinostat daily seven ( 7 ) day prior surgery . On day surgery , patient receive vorinostat . Patients undergo surgery usual , change planning technique procedure . The tumor specimens surgery examine presence quantity mutant VHL protein . Comparisons level mutant VHL protein make tissue bank previous surgical resection 03-N-0164 . Measurements genetic expression vascular endothelial growth factor ( VEGF ) erythropoietin ( EPO ) also perform specimen . Outcome Measures 1 . The presence quantity mutant VHL protein resect hemangioblastoma specimen , include comparison specimen without vorinostat treatment presurgical vorinostat treatment . 2 . Measurement VEGF EPO result resect hemangioblastoma specimen , include comparison specimen without vorinostat treatment presurgical vorinostat treatment .</detailed_description>
	<mesh_term>Von Hippel-Lindau Disease</mesh_term>
	<mesh_term>Hemangioblastoma</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . Adult patient ( age great equal 18 year ) 2 . Known VHL disease arise missense mutation . 3 . Demonstrated clinical progression CNS hemangioblastoma . 4 . Enrolled 03N0164 , Evaluation Neurosurgical Disorders . 5 . Able provide write informed consent . EXCLUSION CRITERIA 1 . Patients previously treat vorinostat . 2 . Significant medical illness investigator opinion adequately control appropriate therapy would compromise patient ability tolerate therapy . 3 . History second cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) , unless complete remission therapy disease minimum 3 year . 4 . Active infection serious concurrent medical illness . 5 . Pregnancy breastfeed . 6 . Presence disease obscure toxicity dangerously alter drug metabolism ( uncontrolled diabetes , liver disease , bleed disorder ) 7 . Currently receive investigational agent . 8 . History allergic reaction attribute compound similar chemical biologic composition vorinostat , valproate . 9 . Currently take another HDACi , valproate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 5, 2016</verification_date>
	<keyword>Missense Mutations</keyword>
	<keyword>Hemangioblastoma</keyword>
	<keyword>Histone Deacytelase Inhibitors</keyword>
	<keyword>Von Hippel-Lindau Disease</keyword>
</DOC>